Brief: Pliant Therapeutics Q3 Net Income USD -41.487 Million
Nov 09 (Reuters) - Pliant Therapeutics Q3 operating expenses USD -47.685 million. * Q3 operating income USD -47.685 million * Q3 EPS USD -0.7
Recent news on Pliant Therapeutics
See all newsBrief: Pliant Therapeutics Announces Presentations At The 2026 Annual Meeting
Brief: Pliant Therapeutics Appoints David Raben, M.D., As Chief Medical Officer
RCS - Redx Pharma Limited - Redx Announces Final Audited Results
RCS - Redx Pharma Limited - Close of Series A; Strengthened Board Composition
U.S. STOCKS ON THE MOVE-Gold miners, Weave Communications, Amylyx Pharmaceuticals